CAMBRIDGE, Mass. and EXTON, Pa., Jan. 05, 2016 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical-stage biopharmaceutical company developing toll-like receptor and RNA therapeutics for patients with cancer and rare diseases, today announced that the company will present at the 34th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13, 2016 at 11:00 a.m. Pacific Time (2:00 p.m. Eastern Time) at the Westin St. Francis in San Francisco. Idera’s Chief Executive Officer, Vincent Milano will present a corporate overview and update and Sudhir Agrawal, D. Phil., Idera’s President of Research will present an overview of the company’s 3rd generation antisense drug development platform.
Live audio webcast of Idera’s presentation will be accessible in the Investors and Media section of Idera’s website at http://www.iderapharma.com. An archived version will also be available on the Company’s website after the event for 90 days. As a convenience to investors, a copy of the company’s presentation will be posted on the Idera corporate website at 8:00 a.m. Eastern Time on Monday, January 11, 2016.
About Idera Pharmaceuticals
Idera Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel nucleic acid-based therapies for the treatment of certain cancers and rare diseases. Idera’s proprietary technology involves using a TLR-targeting technology, to design synthetic oligonucleotide-based drug candidates to act by modulating the activity of specific TLRs. In addition to its TLR programs, Idera is developing a third generation antisense technology platform that it has created using its proprietary technology to inhibit the production of disease-associated proteins by targeting RNA. To learn more about Idera, visit www.iderapharma.com.
Investor and Media Contact Robert Doody VP, IR & Corporate Communications 617-679-5515 (office) 484‐639‐7235 (mobile) firstname.lastname@example.org
Source:Idera Pharmaceuticals, Inc.